Days Sales in Receivables: The average number of days it takes to collect outstanding receivable amounts from customers. Calculated as: Number of Days in Period / Receivable Turnover
Tarsus Pharmaceuticals, Inc. (TARS) had Days Sales in Receivables of 56.36 for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
$118.70M |
|
$-12.59M |
|
$8.31M |
|
$110.39M |
|
$133.23M |
|
$-14.53M |
|
$1.94M |
|
$-12.59M |
|
$-12.59M |
|
$-12.59M |
|
$-12.59M |
|
$-12.59M |
|
$-12.59M |
|
$-14.53M |
|
$-15.45M |
|
42.61M |
|
42.61M |
|
$-0.30 |
|
$-0.30 |
|
| Balance Sheet Financials | |
$501.70M |
|
$5.75M |
|
$32.86M |
|
$534.56M |
|
$117.05M |
|
$72.28M |
|
$82.43M |
|
$199.48M |
|
$335.08M |
|
$327.48M |
|
$335.08M |
|
42.45M |
|
| Cash Flow Statement Financials | |
$-31.78M |
|
$-91.39M |
|
$141.08M |
|
$97.38M |
|
$115.29M |
|
$17.91M |
|
$27.41M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.29 |
|
-- |
|
-- |
|
0.18 |
|
0.22 |
|
93.00% |
|
-12.24% |
|
-12.24% |
|
-- |
|
-10.60% |
|
-10.60% |
|
$-35.28M |
|
-- |
|
-- |
|
-- |
|
0.22 |
|
2.17 |
|
1.60 |
|
|
Days Sales in Receivables |
56.36 |
-3.76% |
|
-3.84% |
|
-2.35% |
|
-3.09% |
|
$7.89 |
|
$-0.83 |
|
$-0.75 |
|